Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Preferred Stock Liabilities (2017 - 2021)

Surgery Partners' Preferred Stock Liabilities history spans 5 years, with the latest figure at $439.7 million for Q1 2021.

  • For Q1 2021, Preferred Stock Liabilities rose 8.7% year-over-year to $439.7 million; the TTM value through Mar 2021 reached $439.7 million, up 8.7%, while the annual FY2020 figure was $434.5 million, 10.0% up from the prior year.
  • Preferred Stock Liabilities for Q1 2021 was $439.7 million at Surgery Partners, up from $434.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $439.7 million in Q1 2021 and bottomed at $310.0 million in Q3 2017.
  • The 5-year median for Preferred Stock Liabilities is $381.2 million (2019), against an average of $381.4 million.
  • The largest annual shift saw Preferred Stock Liabilities grew 10.0% in 2020 before it grew 8.7% in 2021.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $310.0 million in 2017, then rose by 15.9% to $359.3 million in 2018, then increased by 9.94% to $395.0 million in 2019, then increased by 10.0% to $434.5 million in 2020, then increased by 1.2% to $439.7 million in 2021.
  • Per Business Quant, the three most recent readings for SGRY's Preferred Stock Liabilities are $439.7 million (Q1 2021), $434.5 million (Q4 2020), and $424.2 million (Q3 2020).